Navigation Links
Renhuang to Launch New All-Natural Anti-depressant and Nerve Regulation Product - Compound Schisandra Tablets
Date:6/22/2010

HARBIN, China, June 22 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company plans to launch its new all-natural anti-depressant and nerve regulation product - Compound Schisandra Tablets ("Schisandra Tablets"), a single plant based medicine, in July 2010. Renhuang estimates that Schisandra Tablets will generate revenues of RMB 3.0 million (approximately $44,000) in fiscal year 2010.

Schisandra, also known as magnolia vine, has been clinically proven to have significant benefits to the functioning and regulation of the central nervous system and for upper body respiration. According to China Pharmacopoeia, Schisandra is used as a remedy for many ailments, such as: to generate body fluids and alleviate thirst, nourish the kidneys, cure insomnia and palpitations, and is also widely used as treatment for neurasthenia (a term most commonly used in Traditional Chinese medicine to denote a complex of symptoms characterized by chronic fatigue and weakness, loss of memory, and generalized aches and pains).

"Compound Schisandra Tablets are an exciting new plant-based anti-depressant and nerve regulation product, which complements our existing product portfolio, provides additional revenue generation opportunities and strengthens our leading market position in this important and rapidly growing market segment," commented Mr. Shaoming Li, Chairman and Chief Executive Officer of Renhuang. "We plan to extensively promote this new product to instill strong market acceptance amongst our target audience. We expect Schisandra will generate RMB 10.0 million (approximately $1.5 million) in revenue in fiscal year 2011."

ABOUT RENHUANG PHARMACEUTICALS, INC.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to expand its new Compound Schisandra Tablets, achieve its estimated sales and net income estimates for Compound Schisandra Tablets, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    For more information, please contact:

    Company Contact:
     Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Tel:   +86-451-8260-2162
     Email: ir@renhuang.com

    CCG Investor Relations:
     Mr. Mark Collinson, Partner
     Phone: +1-310-954-1343 (Los Angeles)
     Email: mark.collinson@ccgir.com
     Web:   www.ccgirasia.com

     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
2. Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results
3. Renhuang Appoints PricewaterhouseCoopers to Develop a SOX 404 Compliance Program
4. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
5. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 107th China Import and Export Fair
6. Renhuang Elected as Deputy Chair Unit of Heilongjiang Medical Association
7. Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
8. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
9. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
10. Renhuang Schedules Conference Call to Discuss FY 2010 First Quarter Results
11. Renhuang Announces Price Increase on Shengmai Granules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... WARSAW, Ind. , Feb. 5, 2016  Zimmer ... the pricing of the previously announced underwritten secondary offering ... of its stockholders, consisting of affiliates of Blackstone and ... public at an initial price of $96.45 per share. ... of the offering.  Neither Zimmer Biomet nor any of ...
(Date:2/5/2016)... France , Germany , Italy ... ). It includes a 10-year epidemiology forecast for the total prevalent ... sex in these markets. GD epidemiology report is written and developed by ... and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... Feb. 4, 2016  The Senior Care Pharmacy ... Reform Committee Chairman Jason Chaffetz (R-UT) ... today,s hearing , "Developments in the Prescription ... and growing questions about abusive pharmacy benefit manager ... (R-UT) and Ranking Member Elijah Cummings (D-MD) are ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s Day ... tips of your toes. Foot massage, whether administered by a professional masseuse or a ... The American Board of Multiple Specialties in Podiatry (ABMSP) has taken the ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... from across the country gathered at the La Valencia Hotel in San Diego, ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot ... 2015 Best in KLAS: Software & Services for HIT Implementation Support & Staffing ... report independently ranks vendor performance by healthcare executives, managers and clinicians representing over ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is a ... drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect for ... includes a 3D slideshow environment with 1 to 5 focus points per scene, stage ...
(Date:2/5/2016)... ... , ... Calls Blacklist has just been updated by mobile app developer Vlad ... has fixed known bugs within the app. Calls Blacklist allows its users to only ... any of their device’s battery power or memory. It provides a powerful call blocker ...
Breaking Medicine News(10 mins):